PregOMICS—Leveraging systems biology and bioinformatics for drug repurposing in maternal-child health

Jeffrey Adam Goldstein, Lisa A. Bastarache, Joshua C. Denny, Jill M. Pulley, David M. Aronoff*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Obstetric diseases remain underserved and understudied. Drug repurposing—utilization of a drug whose use is accepted in one condition for a different condition—could represent a rapid and low-cost way to identify new therapies that are known to be safe. In diseases of pregnancy, the known safety profile is a strong additional incentive. We describe the techniques and steps used in the use of ‘omics data for drug repurposing. We illustrate these techniques using case studies of published drug repurposing projects. We provide a set of available databases with low barriers to entry which investigators can use to perform their own projects. The promise of ‘omics techniques is unbiased screening, either of all drug targets or of all patients using particular drugs to find which are likely to alter disease risk or progression. However, we caution that reproducibility across the underlying studies, and thus the drugs suggested for repurposing, can be poor. We suggest that improved nosology, for example correlating patient clinical conditions with placental pathology, could yield more robust associations. We conclude that ‘omics-driven drug repurposing represents a potential fruitful path to discover new, safe treatments of obstetric diseases.

Original languageEnglish (US)
Article numbere12971
JournalAmerican Journal of Reproductive Immunology
Volume80
Issue number2
DOIs
StatePublished - Aug 1 2018

Fingerprint

Drug Repositioning
Systems Biology
Computational Biology
Pharmaceutical Preparations
Obstetrics
Motivation
Research Personnel
Databases
Pathology
Safety
Costs and Cost Analysis
Pregnancy
Child Health
Maternal Health
Therapeutics

Keywords

  • GWAS
  • diseases of pregnancy
  • drug repurposing
  • obstetrics
  • ‘omics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

@article{e3e84fc8c8974d1e91705d11305cc907,
title = "PregOMICS—Leveraging systems biology and bioinformatics for drug repurposing in maternal-child health",
abstract = "Obstetric diseases remain underserved and understudied. Drug repurposing—utilization of a drug whose use is accepted in one condition for a different condition—could represent a rapid and low-cost way to identify new therapies that are known to be safe. In diseases of pregnancy, the known safety profile is a strong additional incentive. We describe the techniques and steps used in the use of ‘omics data for drug repurposing. We illustrate these techniques using case studies of published drug repurposing projects. We provide a set of available databases with low barriers to entry which investigators can use to perform their own projects. The promise of ‘omics techniques is unbiased screening, either of all drug targets or of all patients using particular drugs to find which are likely to alter disease risk or progression. However, we caution that reproducibility across the underlying studies, and thus the drugs suggested for repurposing, can be poor. We suggest that improved nosology, for example correlating patient clinical conditions with placental pathology, could yield more robust associations. We conclude that ‘omics-driven drug repurposing represents a potential fruitful path to discover new, safe treatments of obstetric diseases.",
keywords = "GWAS, diseases of pregnancy, drug repurposing, obstetrics, ‘omics",
author = "Goldstein, {Jeffrey Adam} and Bastarache, {Lisa A.} and Denny, {Joshua C.} and Pulley, {Jill M.} and Aronoff, {David M.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1111/aji.12971",
language = "English (US)",
volume = "80",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "2",

}

PregOMICS—Leveraging systems biology and bioinformatics for drug repurposing in maternal-child health. / Goldstein, Jeffrey Adam; Bastarache, Lisa A.; Denny, Joshua C.; Pulley, Jill M.; Aronoff, David M.

In: American Journal of Reproductive Immunology, Vol. 80, No. 2, e12971, 01.08.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PregOMICS—Leveraging systems biology and bioinformatics for drug repurposing in maternal-child health

AU - Goldstein, Jeffrey Adam

AU - Bastarache, Lisa A.

AU - Denny, Joshua C.

AU - Pulley, Jill M.

AU - Aronoff, David M.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Obstetric diseases remain underserved and understudied. Drug repurposing—utilization of a drug whose use is accepted in one condition for a different condition—could represent a rapid and low-cost way to identify new therapies that are known to be safe. In diseases of pregnancy, the known safety profile is a strong additional incentive. We describe the techniques and steps used in the use of ‘omics data for drug repurposing. We illustrate these techniques using case studies of published drug repurposing projects. We provide a set of available databases with low barriers to entry which investigators can use to perform their own projects. The promise of ‘omics techniques is unbiased screening, either of all drug targets or of all patients using particular drugs to find which are likely to alter disease risk or progression. However, we caution that reproducibility across the underlying studies, and thus the drugs suggested for repurposing, can be poor. We suggest that improved nosology, for example correlating patient clinical conditions with placental pathology, could yield more robust associations. We conclude that ‘omics-driven drug repurposing represents a potential fruitful path to discover new, safe treatments of obstetric diseases.

AB - Obstetric diseases remain underserved and understudied. Drug repurposing—utilization of a drug whose use is accepted in one condition for a different condition—could represent a rapid and low-cost way to identify new therapies that are known to be safe. In diseases of pregnancy, the known safety profile is a strong additional incentive. We describe the techniques and steps used in the use of ‘omics data for drug repurposing. We illustrate these techniques using case studies of published drug repurposing projects. We provide a set of available databases with low barriers to entry which investigators can use to perform their own projects. The promise of ‘omics techniques is unbiased screening, either of all drug targets or of all patients using particular drugs to find which are likely to alter disease risk or progression. However, we caution that reproducibility across the underlying studies, and thus the drugs suggested for repurposing, can be poor. We suggest that improved nosology, for example correlating patient clinical conditions with placental pathology, could yield more robust associations. We conclude that ‘omics-driven drug repurposing represents a potential fruitful path to discover new, safe treatments of obstetric diseases.

KW - GWAS

KW - diseases of pregnancy

KW - drug repurposing

KW - obstetrics

KW - ‘omics

UR - http://www.scopus.com/inward/record.url?scp=85046335917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046335917&partnerID=8YFLogxK

U2 - 10.1111/aji.12971

DO - 10.1111/aji.12971

M3 - Article

C2 - 29726581

AN - SCOPUS:85046335917

VL - 80

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 2

M1 - e12971

ER -